Prolonged treatment interruption in chronic HIV infection: a new strategy?
The introduction of highly active antiretroviral therapy in 1995 dramatically decreased AIDS-related events and deaths rates; however, the enthusiasm among the medical and social community was soon limited by the growing incidence of various side-effects that often greatly limited patients' quality of life. The second problem caused by such a complex treatment consisted of sub-optimal adherence, with a consequent higher risk of the development of drug resistance.
Giuntini
Riccardo
R
Infectious Diseases Unit, AOU Careggi, Florence, Italy.
Martinelli
Canio
C
Ambu
Silvia
S
Bartolozzi
Dario
D
Farese
Alberto
A
Boddi
Vieri
V
Leoncini
Francesco
F
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D015331:Cohort Studies; D016049:Didanosine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage
D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016049:Didanosine